5-Amino-1MQ
NNMT inhibitor that increases cellular metabolism and fat oxidation without appetite suppression.
Last updated: August 2026
Category
Metabolic Enhancer
Frequency
Daily oral or injection (community practice, no trial)
Research
Preclinical / Early HumanWhat is 5-Amino-1MQ?
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small molecule inhibitor of NNMT (nicotinamide N-methyltransferase), an enzyme involved in fat cell metabolism. Technically it is not a peptide, but it is sold in the peptide market and used by the same community. By inhibiting NNMT, it may increase NAD+ levels in fat tissue and shift metabolism toward fat burning. Think of it as targeting fat cells at the enzyme level rather than through appetite suppression.
How does NNMT inhibition work? NNMT is overexpressed in obesity and metabolic disease. It consumes SAM (S-adenosylmethionine) and produces 1-methylnicotinamide, depleting methyl donors and slowing metabolism. By blocking NNMT, 5-Amino-1MQ preserves SAM and raises NAD+ levels. Higher NAD+ activates sirtuins which regulate mitochondrial biogenesis and fat oxidation. The result is fat cells that burn more energy and become less efficient at storing fat.
What does the research actually show? Early stage. Promising animal data on fat reduction without calorie restriction. No large human clinical trials yet. In preclinical mouse studies, it prevented obesity even when subjects were fed a high-fat diet. The mechanism is well-understood but the clinical evidence in humans is thin. Position it honestly as an interesting research compound, not a proven weight loss drug.
Unlike GLP-1 peptides that work by suppressing appetite, 5-Amino-1MQ targets metabolism at the cellular level. Semaglutide and tirzepatide make you eat less. 5-Amino-1MQ makes fat cells burn more, at least in mice. Some people combine them, but no trial has tested that combination, so what exists is anecdote rather than evidence, and this page does not publish combination guidance.
5-Amino-1MQ is available in both oral capsule form and injectable form. Oral capsules are more common because most users who want to inject already have GLP-1s for that purpose. In Vietnam, it is available research-grade. Often comes in capsule form rather than injectable, which makes it more accessible for users who do not want to inject. For verified suppliers, see the supply index. Verify purity via the COA guide. For legal context, see the peptide legality guide.
In the biohacking weight loss community, 5-Amino-1MQ is commonly reported alongside retatrutide, tirzepatide or AOD-9604 (community practice, no trial). None of those combinations has been tested in a published study, in animals or in people, so the appeal of pairing appetite suppression with a cellular mechanism is a rationale rather than a result, and this page does not publish combination guidance.
How It Works
NNMT Inhibition: NNMT is overexpressed in obesity and metabolic disease. It consumes SAM and produces 1-methylnicotinamide, depleting methyl donors and slowing metabolism. By blocking NNMT, 5-Amino-1MQ preserves SAM and raises NAD+ levels.
NAD+ Elevation: Higher NAD+ activates sirtuins (particularly SIRT1 and SIRT3) which regulate mitochondrial biogenesis, fat oxidation, and energy expenditure. This effectively raises the metabolic rate of fat cells.
Adipocyte Reprogramming: Preclinical data shows 5-Amino-1MQ can cause fat cells to take on characteristics of "beige" fat: a more metabolically active form that burns energy through thermogenesis rather than storing it.
Benefits
- Increased fat oxidation without appetite suppression
- Boosts NAD+ levels, supporting cellular energy and longevity
- May reduce stubborn fat (visceral and subcutaneous)
- Proposed synergy with GLP-1 peptides (mechanism argument only, no trial has tested the combination)
- Improves metabolic health markers in preclinical models
- Oral bioavailability available (capsule form)
- Anti-aging potential via NAD+ and sirtuin activation
Dosing Described in Research and Labels
| Phase | Dose | Frequency | Duration |
|---|---|---|---|
| Investigational | No established human dose | Oral (research) | Not established |
These figures summarise what published research and approved labels describe. They are educational, not a recommendation or a personal protocol. Any dose, schedule, or decision to use a compound belongs with a licensed prescriber.
Side Effects
Common
- ⚠Mild fatigue in first week (as metabolism shifts)
- ⚠Increased thirst
- ⚠Slight appetite changes
- ⚠Injection site reactions (if using injectable form)
Rare
- •Limited human data available: monitor response closely
- •Potential interactions with methylation pathways
- •Unknown long-term effects in humans
Who Should NOT Use 5-Amino-1MQ
- ✕Pregnancy or breastfeeding
- ✕Active cancer (NNMT can be protective in some cancers: consult oncologist)
- ✕Under 18 years old
- ✕Severe liver disease
- ✕Limited human safety data: use caution
What to Expect
Adjustment phase. Some users report mild fatigue as cellular metabolism shifts. No dramatic changes visible yet.
Increased energy levels reported by most users. Subtle improvements in body composition may begin, especially when combined with exercise.
More noticeable changes in body composition are reported, particularly around the midsection (community practice, no trial). No human trial has measured body composition on this compound at any timepoint, and reported results track concurrent calorie deficits as readily as they track the compound.
Notes from Ho Chi Minh City
5-Amino-1MQ is an oral small molecule, which is its main practical draw in Thao Dien: a capsule with morning coffee adds a metabolic angle to a GLP-1 regimen without another injection. The honest framing the data forces is that human evidence is thin; most of the enthusiasm extrapolates from mouse adipocyte-browning studies, and self-reported effects track concurrent caloric deficits more than any independent metabolic lift. On the Vietnam market, research-grade 5-Amino-1MQ is sourced through cold-chain importers rather than pharmacies. Whether it belongs in a regimen, and at what dose, is a prescriber's call rather than a forum extrapolation.
Sourcing in Vietnam
5-Amino-1MQ has no FDA approval and no DAV-registered pharmaceutical brand in Vietnam. It is not stocked at Long Châu, Pharmacity, FV Hospital, or Vinmec. What circulates here is research-grade material brought in by cold-chain importers, packaged either as 100-capsule bottles at 50mg per capsule or as 200mg injectable vials. Those milligram figures describe how the product is packaged and sold, not a dose: no human dose has been established for this compound. Capsule form is the more common purchase route. See the supplier list and COA guide before purchasing.
FAQ
Q: Can I stack 5-Amino-1MQ with Retatrutide or Tirzepatide?
A: No trial has studied 5-Amino-1MQ alongside a GLP-1 receptor agonist, so there is no evidence describing what that pairing does in people and no published interaction data of any kind. Absence of interaction data is not a finding of safety. The two also sit at completely different evidence tiers: tirzepatide has large randomised human trials and an approved label, retatrutide has one phase 2 trial and no approval anywhere, and every published 5-Amino-1MQ result is preclinical. Whether an unapproved research compound belongs anywhere near a prescribed GLP-1 medicine is a question for the prescriber managing that medicine.
Q: Oral vs injectable 5-Amino-1MQ: which is better?
A: No human trial has compared the two forms, so there is nothing to point at and no basis for calling either better. What can be said factually is that 5-Amino-1MQ is a small molecule rather than a peptide, which is why an oral form exists at all in a market where almost everything else has to be injected. The published evidence behind it is preclinical: NNMT inhibitors from the methylquinolinium series reduced body weight, white adipose mass and adipocyte size in diet-induced obese mice, given systemically (mouse study, not a human dose, PMID 29155147). Which form is appropriate, if either is, is a clinical decision rather than a preference.
Q: How long are cycles for 5-Amino-1MQ?
A: Community practice reports: 8 to 12 week cycles followed by roughly 4 weeks off (community practice, no trial). Disclaimer: no clinical trial has established a human dose, a cycle length or an off period for 5-Amino-1MQ, and there is no approved label in any market to cite instead. The published work is preclinical and mostly in mice. The cycling pattern is a precaution people adopted because nobody has measured what continuous use does in humans, which is a reason for caution rather than a schedule anyone tested. Source from the community-verified supplier list.
Where to Get 5-Amino-1MQ in Vietnam
See our community-verified supplier list with COA verification and cold-chain shipping to Vietnam.
Related Peptides
Research & Sources
- Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity · Kraus D, Yang Q, Kong D, et al. · Nature (2014) (PMID: 24717514)
Foundational paper demonstrating NNMT inhibition prevents obesity in diet-induced mouse models.
- Discovery of 5-amino-1-methylquinolinium as a small molecule NNMT inhibitor · Neelakantan H, Vance V, Wetzel HN, et al. · Biochemical Pharmacology (2018) (PMID: 29208365)
Original synthesis and pharmacological characterization paper for 5-Amino-1MQ as a selective NNMT inhibitor.
- Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice · Neelakantan H, Vance V, Wetzel MD, et al. · Biochemical Pharmacology (2018) (PMID: 29155147)
In vivo evidence that 5-Amino-1MQ reverses obesity and improves metabolic parameters in established obese mice.
- Roles of Nicotinamide N-Methyltransferase in Obesity and Type 2 Diabetes · Liu JR, Deng ZH, Zhu XJ, et al. · BioMed Research International (2021) (PMID: 34368359)
Mechanistic context on NNMT overexpression in human obesity and type 2 diabetes adipose tissue.
Important Disclaimer
Educational content only. Not medical advice. Peptides discussed on this page are not approved by Vietnam’s Ministry of Health (Bộ Y Tế) or the Drug Administration of Vietnam (DAV) for the indications described. Research peptides are not stocked at Long Châu, Pharmacity, or any retail pharmacy in Vietnam. Consult a licensed physician before any use.